The most recent exciting results published of the IMbrave150, a global, multicenter, open-label, phase 3 randomized trial of atezolizumab (PD-L1) plus bevacizumab (VEGF) in patients with untreated unresectable hepatocellular carcinoma showed that the combination was superior in prolonged OS and progression-free survival (PFS) as compared to sorafenib [41]. This evidence concerns the gene CD274 and hepatocellular carcinoma.